BTN3A2 Protein, Human, Recombinant (His & Avi)

BTN3A2/BT3.2 butyrophilin mRNA expression by tumoral cells was previously identified as a prognostic factor in a small cohort of high grade serous epithelial ovarian cancer (HG-EOC).In conclusion, BT3.2 protein is a potential prognostic biomarker for the identification of HG-EOC patients with better outcome. In contrast, high CD206 /CD68 expression is associated with high risk of disease progression.

Pack Size	Availability	Price/USD
100 μg	5 days	$ 418.00
500 μg	5 days	$ 1,670.00
1 mg	5 days	$ 2,800.00

Pack Size

Availability

Price/USD

Quantity

100 μg

5 days

$ 418.00

500 μg

5 days

$ 1,670.00

1 mg

5 days

$ 2,800.00

Description

Species	Human
Expression System	HEK293 Cells
Tag	C-His-Avi
Accession Number	P78410-1
Synonyms	FLJ40011, BTN3A2, BTF4, CD277, BT3.2, BTF3, BT3.3, BTN3.2
Construction	Gln30-Trp248
Protein Purity	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
Molecular Weight	26.5 kDa (predicted). Due to glycosylation, the protein migrates to 27-33 kDa based on Tris-Bis PAGE result.

Endotoxin	< 1 EU/μg by the LAL method.
Formulation	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization.
Reconstitution	Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.
Stability & Storage	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at-80℃. For reconstituted proteinsolutions, the solution can be stored at -20°c to -80'c for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
Shipping	In general, Lyophilized powders are shipping with blue ice.
Research Background	BTN3A2/BT3.2 butyrophilin mRNA expression by tumoral cells was previously identified as a prognostic factor in a small cohort of high grade serous epithelial ovarian cancer (HG-EOC).In conclusion, BT3.2 protein is a potential prognostic biomarker for the identification of HG-EOC patients with better outcome. In contrast, high CD206 /CD68 expression is associated with high risk of disease progression.